CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:AFX - DE0005313704 - Common Stock
43.62 EUR
+1.34 (+3.17%)
We assign a fundamental rating of 5 out of 10 to AFX. AFX was compared to 63 industry peers in the Health Care Equipment & Supplies industry. AFX has only an average score on both its financial health and profitability. AFX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AFX had positive earnings in the past year.
AFX had a positive operating cash flow in the past year.
AFX had positive earnings in each of the past 5 years.
AFX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of 4.49%, AFX is doing good in the industry, outperforming 60.32% of the companies in the same industry.
AFX has a Return On Equity (7.51%) which is comparable to the rest of the industry.
AFX has a Return On Invested Capital (4.74%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for AFX is in line with the industry average of 9.81%.
The 3 year average ROIC (9.30%) for AFX is well above the current ROIC(4.74%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.49% | ||
| ROE | 7.51% | ||
| ROIC | 4.74% |
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
1.3 Margins
AFX has a Profit Margin (7.19%) which is comparable to the rest of the industry.
In the last couple of years the Profit Margin of AFX has declined.
With a Operating Margin value of 8.55%, AFX perfoms like the industry average, outperforming 46.03% of the companies in the same industry.
In the last couple of years the Operating Margin of AFX has declined.
AFX's Gross Margin of 52.43% is in line compared to the rest of the industry. AFX outperforms 41.27% of its industry peers.
In the last couple of years the Gross Margin of AFX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.55% | ||
| PM (TTM) | 7.19% | ||
| GM | 52.43% |
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AFX is still creating some value.
The number of shares outstanding for AFX has been reduced compared to 1 year ago.
Compared to 5 years ago, AFX has less shares outstanding
The debt/assets ratio for AFX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.25 indicates that AFX is not in any danger for bankruptcy at the moment.
AFX's Altman-Z score of 3.25 is fine compared to the rest of the industry. AFX outperforms 65.08% of its industry peers.
AFX has a debt to FCF ratio of 7.17. This is a slightly negative value and a sign of low solvency as AFX would need 7.17 years to pay back of all of its debts.
AFX has a Debt to FCF ratio (7.17) which is comparable to the rest of the industry.
AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
AFX has a Debt to Equity ratio (0.27) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 7.17 | ||
| Altman-Z | 3.25 |
ROIC/WACC0.7
WACC6.79%
2.3 Liquidity
A Current Ratio of 2.04 indicates that AFX has no problem at all paying its short term obligations.
AFX has a Current ratio of 2.04. This is in the better half of the industry: AFX outperforms 63.49% of its industry peers.
AFX has a Quick Ratio of 1.17. This is a normal value and indicates that AFX is financially healthy and should not expect problems in meeting its short term obligations.
AFX has a Quick ratio (1.17) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.04 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
Measured over the past 5 years, AFX shows a small growth in Earnings Per Share. The EPS has been growing by 2.35% on average per year.
AFX shows a small growth in Revenue. In the last year, the Revenue has grown by 5.50%.
Measured over the past years, AFX shows a small growth in Revenue. The Revenue has been growing by 7.20% on average per year.
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%
3.2 Future
Based on estimates for the next years, AFX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.55% on average per year.
AFX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.84% yearly.
EPS Next Y-14.52%
EPS Next 2Y1.17%
EPS Next 3Y7.8%
EPS Next 5Y13.55%
Revenue Next Year6.32%
Revenue Next 2Y5.59%
Revenue Next 3Y6.13%
Revenue Next 5Y6.84%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 25.51 indicates a quite expensive valuation of AFX.
Compared to the rest of the industry, the Price/Earnings ratio of AFX indicates a somewhat cheap valuation: AFX is cheaper than 68.25% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of AFX to the average of the S&P500 Index (26.28), we can say AFX is valued inline with the index average.
A Price/Forward Earnings ratio of 21.20 indicates a rather expensive valuation of AFX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AFX is on the same level as its industry peers.
AFX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.52.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.51 | ||
| Fwd PE | 21.2 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AFX is valued a bit cheaper than the industry average as 68.25% of the companies are valued more expensively.
The rest of the industry has a similar Price/Free Cash Flow ratio as AFX.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.03 | ||
| EV/EBITDA | 12.68 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)10.88
EPS Next 2Y1.17%
EPS Next 3Y7.8%
5. Dividend
5.1 Amount
AFX has a Yearly Dividend Yield of 1.39%.
Compared to an average industry Dividend Yield of 2.14, AFX pays a bit more dividend than its industry peers.
Compared to the average S&P500 Dividend Yield of 2.31, AFX is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.39% |
5.2 History
On average, the dividend of AFX grows each year by 15.07%, which is quite nice.
Dividend Growth(5Y)15.07%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
AFX pays out 33.69% of its income as dividend. This is a sustainable payout ratio.
AFX's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP33.69%
EPS Next 2Y1.17%
EPS Next 3Y7.8%
FRA:AFX (12/9/2025, 7:00:00 PM)
43.62
+1.34 (+3.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners25.58%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.90B
Revenue(TTM)2.18B
Net Income(TTM)155.89M
Analysts73.64
Price Target55.56 (27.37%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.39% |
Yearly Dividend1.11
Dividend Growth(5Y)15.07%
DP33.69%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.71%
Min EPS beat(2)-36.67%
Max EPS beat(2)13.25%
EPS beat(4)2
Avg EPS beat(4)-5.53%
Min EPS beat(4)-36.67%
Max EPS beat(4)37.18%
EPS beat(8)6
Avg EPS beat(8)8.89%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.29%
Min Revenue beat(2)0.82%
Max Revenue beat(2)3.76%
Revenue beat(4)3
Avg Revenue beat(4)0.58%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.67%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.39%
EPS NQ rev (1m)-4.88%
EPS NQ rev (3m)-4.88%
EPS NY rev (1m)-0.85%
EPS NY rev (3m)-4.94%
Revenue NQ rev (1m)-0.2%
Revenue NQ rev (3m)-0.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.51 | ||
| Fwd PE | 21.2 | ||
| P/S | 1.8 | ||
| P/FCF | 47.03 | ||
| P/OCF | 19.95 | ||
| P/B | 1.88 | ||
| P/tB | 10.06 | ||
| EV/EBITDA | 12.68 |
EPS(TTM)1.71
EY3.92%
EPS(NY)2.06
Fwd EY4.72%
FCF(TTM)0.93
FCFY2.13%
OCF(TTM)2.19
OCFY5.01%
SpS24.26
BVpS23.21
TBVpS4.34
PEG (NY)N/A
PEG (5Y)10.88
Graham Number29.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.49% | ||
| ROE | 7.51% | ||
| ROCE | 6.52% | ||
| ROIC | 4.74% | ||
| ROICexc | 4.83% | ||
| ROICexgc | 12.2% | ||
| OM | 8.55% | ||
| PM (TTM) | 7.19% | ||
| GM | 52.43% | ||
| FCFM | 3.82% |
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
ROICexc(3y)9.4%
ROICexc(5y)9.95%
ROICexgc(3y)15.11%
ROICexgc(5y)14.88%
ROCE(3y)12.78%
ROCE(5y)13.55%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-4.98%
ROICexc growth 3Y-28.53%
ROICexc growth 5Y-15.45%
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 7.17 | ||
| Debt/EBITDA | 1.68 | ||
| Cap/Depr | 73.33% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | 13.7 | ||
| Cash Conversion | 57.69% | ||
| Profit Quality | 53.21% | ||
| Current Ratio | 2.04 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 3.25 |
F-Score4
WACC6.79%
ROIC/WACC0.7
Cap/Depr(3y)128.62%
Cap/Depr(5y)113.53%
Cap/Sales(3y)5.71%
Cap/Sales(5y)4.9%
Profit Quality(3y)45.51%
Profit Quality(5y)74.23%
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
EPS Next Y-14.52%
EPS Next 2Y1.17%
EPS Next 3Y7.8%
EPS Next 5Y13.55%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%
Revenue Next Year6.32%
Revenue Next 2Y5.59%
Revenue Next 3Y6.13%
Revenue Next 5Y6.84%
EBIT growth 1Y-40.66%
EBIT growth 3Y-19.39%
EBIT growth 5Y-5.98%
EBIT Next Year56.91%
EBIT Next 3Y26.03%
EBIT Next 5Y19.93%
FCF growth 1Y-30.57%
FCF growth 3Y-31.55%
FCF growth 5Y-11.27%
OCF growth 1Y-1.41%
OCF growth 3Y-11.98%
OCF growth 5Y2.4%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
Can you provide the valuation status for CARL ZEISS MEDITEC AG - BR?
ChartMill assigns a valuation rating of 2 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Overvalued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 5 / 10.
What is the valuation of CARL ZEISS MEDITEC AG - BR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 25.51 and the Price/Book (PB) ratio is 1.88.
What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 6 / 10.